Delaware
|
|
001-34703
|
|
20-0028718
|
||
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
||
|
|
|
||||
6120 Windward Parkway
Suite 290
Alpharetta, Georgia
|
|
30005
|
||||
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Not Applicable
|
(Former name or former address if changed since last report.)
|
•
|
C. Daniel Myers, co-founder of the Company, retired as Chief Executive Officer and became a consultant to the Company and Non-Executive Chairman of the Board. Mr. Myers’ prior employment agreement terminated; the Succession and Consulting Agreement (the “Consulting Agreement”) previously entered into by and between the Company and Mr. Myers, and filed with the SEC with the Prior Form 8-K, became effective; and Mr. Myers now serves as Non-Executive Chairman of the Board. Additional details regarding the Consulting Agreement and Mr. Myers’ appointment as Non-Executive Chairman of the Board can be found in the Prior Form 8-K, including the full text of the Consulting Agreement attached to the Prior Form 8-K as Exhibit 10.1.
|
•
|
Richard S. Eiswirth, Jr. was promoted from President and Chief Financial Officer to President and Chief Executive Officer and assumed the day-to-day leadership of the Company. Mr. Eiswirth also joined the Board. He will not serve on any Board committees.
|
•
|
J. Philip Jones, formerly the Company’s Vice President of Finance, assumed the role of Chief Financial Officer.
|
•
|
Philip Ashman, Ph. D, formerly the Company’s Senior Vice President, Managing Director Europe, assumed the roles of Chief Operating Officer and Senior Vice President Commercial Operations Europe.
|
C. Daniel Myers
|
Non-Executive Chairman and Class I Director
(term expires in 2020)
|
James R. Largent
|
Class I Lead Independent Director (term expires in 2020)
|
Calvin W. Roberts, M.D.
|
Class I Director (term expires in 2020)
|
Garheng Kong, M.D., Ph.D.
|
Class II Director (term expires in 2021)
|
Richard S. Eiswirth, Jr.
|
Class II Director (term expires in 2021)
|
Mary Szela
|
Class II Director (term expires in 2021)
|
Mark J. Brooks
|
Class III Director (term expires in 2019)
|
Brian K. Halak, Ph.D.
|
Class III Director (term expires in 2019)
|
Peter J. Pizzo, III
|
Class III Director (term expires in 2019)
|
Richard S. Eiswirth, Jr.
|
Chief Executive Officer
|
J. Philip Jones
|
Chief Financial Officer
|
Philip Ashman
|
Chief Operating Officer, Senior Vice President Commercial Operations Europe
|
David Holland
|
Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets
|
Kenneth Green, Ph.D.
|
Senior Vice President, Chief Scientific Officer and Global Head of Research*
|
Exhibit
No.
|
|
Description
|
10.1
|
|
|
10.2
|
|
|
ALIMERA SCIENCES, INC.
|
|
|
|
|
Dated: January 2, 2019
|
By:
|
/s/ J. Philip Jones
|
|
Name:
|
J. Philip Jones
|
|
Title:
|
Chief Financial Officer
|